Literature DB >> 25994013

Atrial fibrillation (chronic).

Deirdre A Lane1, Christopher J Boos, Gregory Y H Lip.   

Abstract

INTRODUCTION: Atrial fibrillation is a supraventricular tachyarrhythmia characterised by the presence of fast and uncoordinated atrial activation leading to reduced atrial mechanical function. Risk factors for atrial fibrillation include increasing age, male sex, co-existing cardiac and thyroid disease, pyrexial illness, electrolyte imbalance, cancer, and co-existing infection. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of oral medical treatments to control heart rate in people with chronic (defined as longer than 1 week for this review) non-valvular atrial fibrillation? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found four studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: beta-blockers (rate-limiting, with or without digoxin), calcium-channel blockers (with or without digoxin), and digoxin.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25994013      PMCID: PMC4439734     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  17 in total

1.  Probability of stroke: a risk profile from the Framingham Study.

Authors:  P A Wolf; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1991-03       Impact factor: 7.914

2.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

3.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.

Authors:  F D R Hobbs; D A Fitzmaurice; J Mant; E Murray; S Jowett; S Bryan; J Raftery; M Davies; G Lip
Journal:  Health Technol Assess       Date:  2005-10       Impact factor: 4.014

4.  Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study.

Authors:  K K Koh; J H Song; K S Kwon; H B Park; S H Baik; Y S Park; H H In; T H Moon; G S Park; S K Cho
Journal:  Int J Cardiol       Date:  1995-11-24       Impact factor: 4.164

5.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?

Authors:  Aleem U Khand; Andrew C Rankin; William Martin; Jacqueline Taylor; Islay Gemmell; John G F Cleland
Journal:  J Am Coll Cardiol       Date:  2003-12-03       Impact factor: 24.094

6.  Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation.

Authors:  Robby Nieuwlaat; Luc W Eurlings; John G Cleland; Stuart M Cobbe; Panos E Vardas; Alessandro Capucci; José L López-Sendòn; Joan G Meeder; Yigal M Pinto; Harry J G M Crijns
Journal:  J Am Coll Cardiol       Date:  2009-05-05       Impact factor: 24.094

7.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

8.  Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation.

Authors:  R Lang; H O Klein; E Weiss; D David; P Sareli; A Levy; J Guerrero; E Di Segni; E Kaplinsky
Journal:  Chest       Date:  1983-03       Impact factor: 9.410

9.  Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation.

Authors:  Sara R Ulimoen; Steve Enger; Jonas Carlson; Pyotr G Platonov; Are H Pripp; Michael Abdelnoor; Harald Arnesen; Knut Gjesdal; Arnljot Tveit
Journal:  Am J Cardiol       Date:  2012-10-27       Impact factor: 2.778

10.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; Deirdre A M van der Kuip; Albert Hofman; Jan A Kors; Gerard van Herpen; Bruno H Ch Stricker; Theo Stijnen; Gregory Y H Lip; Jacqueline C M Witteman
Journal:  Eur Heart J       Date:  2006-03-09       Impact factor: 29.983

View more
  3 in total

Review 1.  Genetic and non-genetic risk factors associated with atrial fibrillation.

Authors:  Lindsay J Young; Steve Antwi-Boasiako; Joel Ferrall; Loren E Wold; Peter J Mohler; Mona El Refaey
Journal:  Life Sci       Date:  2022-04-03       Impact factor: 6.780

2.  Effect of the Alterations in Contractility and Morphology Produced by Atrial Fibrillation on the Thrombosis Potential of the Left Atrial Appendage.

Authors:  Danila Vella; Alessandra Monteleone; Giulio Musotto; Giorgia Maria Bosi; Gaetano Burriesci
Journal:  Front Bioeng Biotechnol       Date:  2021-02-26

3.  The Role of Patient-Specific Morphological Features of the Left Atrial Appendage on the Thromboembolic Risk Under Atrial Fibrillation.

Authors:  Giulio Musotto; Alessandra Monteleone; Danila Vella; Sofia Di Leonardo; Alessia Viola; Giuseppe Pitarresi; Bernardo Zuccarello; Antonio Pantano; Andrew Cook; Giorgia M Bosi; Gaetano Burriesci
Journal:  Front Cardiovasc Med       Date:  2022-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.